Core Viewpoint - Merck & Co. Inc. will not exercise its option for Evaxion A/S's Gonorrhea vaccine candidate EVX-B2, allowing Evaxion to retain global rights and seek another licensing partner [1][2]. Group 1: Company Developments - Evaxion's Gonorrhea vaccine candidate EVX-B2 has shown protective effects against the bacteria in preclinical studies, yet no vaccine has been approved for Gonorrhea despite over 80 million infections annually [2]. - Evaxion's CEO, Helen Tayton-Martin, stated that the decision by Merck does not affect the company's cash runway, which extends to the second half of 2027 [2]. - Merck's option was specifically for the protein-based version of EVX-B2, while Evaxion is also developing an mRNA version in collaboration with Afrigen Biologics [3]. Group 2: Financial Aspects - Evaxion received a cash payment of $7.5 million from Merck and is eligible for future milestone payments of up to $592 million, along with royalties on net sales for the EVX-B3 vaccine [4]. - Merck will take full responsibility for the further development and associated costs of the EVX-B3 vaccine [4]. Group 3: Market Reaction - Following the news, Evaxion's stock (EVAX) experienced a decline of 14.61%, trading at $4.91 [5].

Core Insights - Evaxion A/S has announced promising new data for its AML vaccine candidate, EVX-04, which shows strong T-cell responses and effective tumor growth prevention in preclinical models [1][5][10] - The data was presented at the American Society of Hematology Annual Meeting, highlighting the company's engagement with the scientific community and potential business partners [2] - The AI-Immunology™ platform has been instrumental in identifying novel ERV tumor antigens, which are targeted by EVX-04, showcasing the platform's unique capabilities in cancer vaccine development [3][4][11] Company Overview - Evaxion A/S is a clinical-stage TechBio company focused on developing AI-Immunology™ powered vaccines, with a commitment to transforming patient care through innovative immunotherapies [12] - The company’s proprietary AI platform enables the identification of therapeutically relevant tumor antigens, which are crucial for the development of effective cancer vaccines [11][12] Product Details - EVX-04 is designed as an off-the-shelf therapeutic cancer vaccine specifically for acute myeloid leukemia (AML), addressing a significant unmet medical need due to the high mortality rates associated with the disease [10] - The vaccine targets non-conventional ERV tumor antigens, which are selectively expressed in tumors but absent in normal tissues, making them ideal candidates for cancer immunotherapy [4][10] AML Context - Acute myeloid leukemia (AML) is characterized by high mortality rates and limited treatment options, with a median age of diagnosis at 68 years [8][9] - Approximately 50% of AML patients are not fit for intensive treatment, leading to a low overall survival rate of 25% over three years for those receiving standard low-intensity chemotherapy [9]

Core Insights - Several biotechnology and pharmaceutical companies experienced significant gains in after-hours trading due to corporate updates and upcoming event announcements [1] Company Updates - Jasper Therapeutics, Inc. (JSPR) saw a 21.51% increase to $2.09 after hours, following the announcement of a webinar on December 2 to present findings from the BEACON study and preliminary data from the ETESIAN study [2] - NRx Pharmaceuticals, Inc. (NRXP) rose 13.39% to $2.71 after hours, with the CEO scheduled to present at NobleCon21 on December 3, discussing the company's expanded focus and clinical revenue progress [3] - Unicycive Therapeutics, Inc. (UNCY) increased by 5.42% to $6.33, with the CEO participating in two upcoming events, although no new announcements were made on Monday [4] - Spruce Biosciences, Inc. (SPRB) shares rose 4.68% to $87.00 after reporting a net loss of $8.2 million for the quarter ending September 30, 2025, an improvement from a net loss of $8.7 million in the previous year [5] - Evaxion A/S (EVAX) added 3.96% to $5.65, announcing progress in its CMV vaccine program with new protective data and ongoing preclinical development [6] - Solana Company (HSDT) gained 3.48% to $3.87, reporting a net loss of $352.8 million for the third quarter, a significant increase from a net loss of $3.7 million in the prior-year period, with revenue totaling $697,000 [7] - Protara Therapeutics, Inc. (TARA) rose 5.04% to $7.08, planning a conference call on December 3 to review interim data from its Phase 2 trial of TARA-002 in bladder cancer patients [8]

Group 1 - Evaxion (NASDAQ:EVAX) is identified as a promising investment opportunity with significant upside potential, highlighted by an increase in price target from $6 to $11 by Lake Street analyst Thomas Flaten, who maintains a Buy rating on the shares [1][2] - The recent announcement of two-year Phase 2 data for Evaxion's personalized cancer vaccine, EVX-01, in advanced melanoma has contributed to this positive sentiment, indicating the vaccine's potential in treating multiple advanced solid cancers [2] - EVX-01 is recognized as Evaxion's lead clinical asset, and the positive data not only supports the efficacy of the vaccine but also validates Evaxion's overall platform, especially in light of Merck & Co. Inc.'s option exercise for EVX-B3 [2][3] Group 2 - Evaxion is a clinical-stage biotech company focused on developing AI-powered immunology vaccines, previously known as Evaxion Biotech until its name change in May 2025 [3] - Merck & Co. Inc. is a key player in the healthcare sector, providing a range of products including human health pharmaceuticals, veterinary pharmaceuticals, and vaccines [3]

Core Insights - Evaxion A/S will present data from its phase 2 trial of the personalized cancer vaccine EVX-01 at the ESMO Congress 2025, highlighting its clinical efficacy, immunogenicity, and safety [1][2][10] Group 1: Presentation Details - The presentation will include two-year clinical efficacy, immunogenicity, and safety data, focusing on overall response rates, deepened response rates, and durability of response [2][10] - The oral session is scheduled for October 17, 2025, at 14:10 CEST, with Dr. Muhammad Adnan Khattak as the presenter [8][10] Group 2: Clinical Trial Insights - EVX-01, designed using Evaxion's AI-Immunology™ platform, is being evaluated for advanced melanoma treatment, showing a 69% overall response rate in previous trials [5][6] - The phase 2 trial combines EVX-01 with MSD's KEYTRUDA® (pembrolizumab), with each vaccine tailored to the individual patient's biology [7] Group 3: Company Background - Evaxion is a clinical-stage TechBio company focused on AI-powered vaccines, with a commitment to developing personalized immunotherapies for cancer and infectious diseases [14]

Core Insights - Evaxion Biotech A/S will participate in the World Vaccine Congress from April 21-24, 2025, in Washington, D.C., showcasing its AI-Immunology™ powered vaccine development [1][3] - The company will present two key topics: the application of its AI-Immunology™ platform for cancer vaccine target discovery and for infectious disease vaccine target discovery [2][4] Company Overview - Evaxion is a clinical-stage TechBio company that utilizes its proprietary AI-Immunology™ platform to develop innovative immunotherapies for cancer and infectious diseases [5] - The company has a clinical-stage oncology pipeline focused on personalized vaccines and a preclinical pipeline addressing bacterial and viral diseases with significant unmet medical needs [5] Event Details - Birgitte Rønø, Chief Scientific Officer, will present on April 23, 2025, at 11:40 ET regarding AI-powered antigen target discovery for cancer vaccines [4] - Pär Comstedt, Vice President of Infectious Disease Vaccine Development, will present on the same day at 15:10 ET about AI-powered target discovery for infectious disease vaccines [4]

Core Insights - Evaxion Biotech A/S has made significant advancements in business development, research, and financing, achieving key milestones in 2024 and early 2025 [2][3] - The company is focused on executing its business development strategy, continuing the EVX-01 phase 2 trial, and enhancing its AI-Immunology™ platform [5][6] - Financially, Evaxion reported a revenue increase to $3.3 million in 2024, compared to $0.1 million in 2023, primarily due to a licensing agreement with MSD [25] Business Highlights - Evaxion completed dosing in the EVX-01 phase 2 trial in January 2025, marking a significant milestone [3] - The company aims to launch an automated lead vaccine candidate design module and secure at least two new business agreements in 2025 [7][19] - A partnership with MSD on two vaccine candidates is progressing towards potential option exercise in the second half of 2025 [8][14] Research & Development Update - The EVX-01 trial is on track for a two-year clinical efficacy readout, with one-year data showing a 69% overall response rate [12][11] - Evaxion is advancing a novel precision cancer vaccine concept targeting ERV tumor antigens, with a lead candidate expected in the second half of 2025 [13] - The AI-Immunology™ platform has been enhanced to predict toxin antigens, improving the development of bacterial vaccines [17][18] Financial Overview - As of December 31, 2024, cash and cash equivalents were $6.0 million, up from $5.6 million in 2023, with a net loss of $10.6 million for the year [24][27] - Research and development expenses decreased to $10.5 million in 2024 from $11.9 million in 2023, reflecting cost efficiencies [25] - The company expects operational cash burn of approximately $14 million in 2025, maintaining cost control while increasing activity levels [6]